Decision and Details
European Patent OfficeReceipt of notification of intention to grant a European patent relating to combination pharmaceuticals comprising the BTK inhibitor docirbrutinib (AS-1763) and BCL-2 inhibitors such as venetoclax
Following its examination, the European Patent Office determined that the invention merits the grant of patent rights. This will further strengthen the European patent portfolio for docirbrutinib.
| Item | Details |
|---|---|
| Matter Covered | Receipt of notification of intention to grant a European patent relating to combination pharmaceuticals comprising the BTK inhibitor docirbrutinib (AS-1763) and BCL-2 inhibitors such as venetoclax |
| Decision-Making Body | European Patent Office |
| Decision Date | 29 June 2026 (date of disclosure; the date on which the notification of intention to grant the patent was received is Not disclosed) |
| Quantity / scale | Application number: No. 21750742.5 |
| Reason | Following its examination, the European Patent Office determined that the invention merits the grant of patent rights. This will further strengthen the European patent portfolio for docirbrutinib. |
| Governing Rule | Rule 71(3) |
| Future plans | The patent is expected to be registered after completion of certain procedures. The Company will continue to actively work to strengthen the patent portfolios for its development products. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following its examination, the European Patent Office determined that the invention merits the grant of patent rights. The Company stated that this decision to grant the patent will further strengthen its European patent portfolio for docirbrutinib.